Consideration of a New Definition of Clinically Relevant Myocardial Infarction After Coronary Revascularization | SCAI
Jul 25th 2013
Emmanouil S. Brilakis, MD, PhD, FSCAI
(Author)
Elizabeth M. Holper, MD, MPH, FSCAI
(Author)
Lloyd W. Klein, MD, MSCAI
(Author)
Roxana Mehran, MD, MSCAI
(Author)
Issam D. Moussa, MD, MBA, FSCAI
(Author)
John P. Reilly, MD, FSCAI
(Author)
Binita Shah, MD, FSCAI
(Author)
Gregg W. Stone, MD, MSCAI
(Author)
Gilbert Zoghbi, MD, FSCAI
(Author)
Clinical Documents Consensus Statement Icon

Consideration of a New Definition of Clinically Relevant Myocardial Infarction After Coronary Revascularization

Consensus Statement

An expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI)

Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post-procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)‐related MI (type 4a) and coronary artery bypass grafting (CABG)‐related MI (type 5) which are of uncertain prognostic importance. In addition, for both MI types cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK‐MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than employing an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large‐scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a “clinically relevant MI.” The present document introduces a new definition for "clinically relevant MI" after coronary revascularization (PCI or CABG) which is applicable for use in clinical trials, patient care, and quality outcomes assessment.

Read the Statement

All authors: Issam D. Moussa, MD, MBA, FSCAI; Lloyd W. Klein, MD, MSCAI; Binita Shah, MD, FSCAI; Roxana Mehran, MD, MSCAI; Michael J. Mack, MD; Emmanouil S. Brilakis, MD, PhD, FSCAI; John P. Reilly, MD, FSCAI; Gilbert Zoghbi, MD, FSCAI; Elizabeth Holper, MD, MPH, FSCAI; and Gregg W. Stone, MD, MSCAI.

Other Guidance Documents

Evidence-based recommendations that promote optimal patient care based on current state-of-the-art science in interventional cardiology. 

All Clinical Documents

© Society for Cardiovascular Angiography & Interventions

SCAI® is a registered trademark of the Society for Cardiovascular Angiography & Interventions.

All content found on the Society for Cardiovascular Angiography & Interventions website (www.scai.org) including text, images, audio, video, or other formats is created for informational purposes only. Links to other content are to be taken at your own risk. SCAI is not responsible for the content or claims of external websites.

Get in touch

1100 17th Street NW, Suite 400, Washington, DC 20036
202-741-9854 TEL
800-992-7224 TOLL-FREE
800-863-5202 FAX
[email protected]

Connect

Follow us on social media.